RA CAPITAL MANAGEMENT L.P. 13D and 13G filings for ARS Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-10-01 9:19 pm Purchase | 2025-09-29 | 13D | ARS PHARMACEUTICALS, INC SPRY | RA CAPITAL MANAGEMENT L.P. | 10,940,977 11.100% | 80,000 (+0.74%) | Filing |
| 2024-03-29 4:14 pm Purchase | 2024-03-27 | 13D | ARS PHARMACEUTICALS, INC SPRY | RA CAPITAL MANAGEMENT L.P. | 10,860,977 11.300% | 1,401,299 (+14.81%) | Filing |
| 2023-09-25 4:30 pm Purchase | 2023-09-21 | 13D | ARS PHARMACEUTICALS, INC SPRY | RA CAPITAL MANAGEMENT L.P. | 9,459,678 9.900% | 2,700,000 (+39.94%) | Filing |
| 2023-08-31 5:25 pm Purchase | 2023-08-29 | 13D | ARS PHARMACEUTICALS, INC SPRY | RA CAPITAL MANAGEMENT L.P. | 6,759,678 7.070% | 5,017,492 (+288.00%) | Filing |
| 2022-02-14 4:11 pm Unchanged | 2021-12-31 | 13G | ARS PHARMACEUTICALS, INC SPRY | RA CAPITAL MANAGEMENT L.P. | 1,742,186 4.970% | 0 (Unchanged) | Filing |